Abstract
Influence of bronchial asthma (BA) severity on physical development in children patients was evaluated in comparison with healthy population. Materials and Methods. 1042 children and adolescents (768 boys) with atopic BA were evaluated. All children underwent standard examination in a clinical setting, including anthropometry. The control group included 875 healthy children of a comparable age (423 boys). Results. The fraction of patients with the normal, lower, and increased height among the whole group of patients with BA is close to the corresponding values in the healthy population (χ2 = 3.32, p = 0.65). The fraction of BA patients with the reduced physical development is increased monotonically and significantly when the BA severity increases: healthy group, 8.2% (72/875), BA intermittent, 4.2% (6/144), BA mild persistent 9% (47/520), BA moderate persistent, 11.7% (36/308), and BA severe persistent, 24.3% (17/70) (χ2 = 45.6, p = 0,0009). Conclusion. The fraction of the children with the reduced height is increased monotonically and significantly in the groups of increasing BA severities. At the same time, the fraction of such children in groups of intermittent and mild persistent BA practically does not differ from the conditionally healthy peers.
Highlights
The connection between the physical development, nutritive status, and the disease course features in the patients with bronchial asthma (BA) attracts close attention [1,2,3]
Several studies connected the negative impact of BA on children physical development to nutritional features and the pharmaceuticals used in the BA therapy [6, 7]
Mild intermittent BA was diagnosed in 144 patients and mild persistent BA in 520 patients, moderately severe BA was found in 308 children, and 70 patients had severe BA
Summary
The connection between the physical development, nutritive status, and the disease course features in the patients with bronchial asthma (BA) attracts close attention [1,2,3]. Several studies connected the negative impact of BA on children physical development to nutritional features (eliminative diets at a food sensitization) and the pharmaceuticals used in the BA therapy [6, 7]. It was suggested that children with BA having night symptoms can have disturbances of night secretion of somatotropic hormone. In turn, can cause their growth inhibition. At present, this hypothesis is not commonly accepted because no abnormalities in the Canadian Respiratory Journal urine excretion of somatotropic hormone were found in the BA patients [8]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
